EMAIL THIS PAGE TO A FRIEND

Arthritis & rheumatology (Hoboken, N.J.)

Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors.


PMID 25989238

Abstract

To determine the development of systemic lupus erythematosus (SLE) in NZM 2328 (NZM) mice deficient in 2 BAFF receptors. NZM.BR-3(-/-) .BCMA(-/-) , NZM.BR-3(-/-) .TACI(-/-) , and NZM.BCMA(-/-) .TACI(-/-) mice were evaluated on the clinical, pathologic, serologic, and cellular levels. BAFF receptor expression and lymphocyte phenotype were assessed by flow cytometry, IgG-secreting cells by enzyme-linked immunospot assay, B cell responsiveness to BAFF and generation of Treg cells by in vitro culture, serum BAFF and total IgG and IgG autoantibody levels by enzyme-linked immunosorbent assay, renal immunopathology by immunofluorescence and histologic analyses, and clinical disease by assessment of proteinuria and mortality. Renal immunopathology and clinical disease were attenuated in NZM.BR-3(-/-) .BCMA(-/-) and NZM.BR-3(-/-) .TACI(-/-) mice but were accelerated in NZM.BCMA(-/-) .TACI(-/-) mice. Accelerated disease was associated with increases in B cells, IgG-secreting cells, serum autoantibody levels, and T cells (especially CD4+ activated memory cells), whereas attenuated disease was associated with reductions in many of these parameters. Serum BAFF levels were increased in all double-deficient NZM mice. Exogenous BAFF promoted the in vitro survival of B cells from NZM.BCMA(-/-) .TACI(-/-) or NZM wild-type mice but not those from NZM.BR-3(-/-) .BCMA(-/-) or NZM.BR-3(-/-) .TACI(-/-) mice. In vitro generation of Treg cells was reduced in NZM.BCMA(-/-) .TACI(-/-) mice, but not in NZM.BR-3(-/-) .BCMA(-/-) or NZM.BR-3(-/-) .TACI(-/-) mice. Elimination of B lymphocyte stimulator receptor 3 (BR-3) and TACI or BR-3 and BCMA inhibits the development of SLE in NZM mice. Selective targeting of BR-3 plus TACI or BR-3 plus BCMA may be an efficacious therapeutic approach in human SLE.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA003563
Anti-C3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA020432
Anti-C3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
GW20073F Anti-Complement C3 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
HPA026872
Anti-FCER1G antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2700389
Anti-FCER1G antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2106731
Anti-FCER1G antibody produced in rabbit, affinity isolated antibody
SAB1405799
Anti-FCER2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA008928
Anti-FCER2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1408575
Anti-FCER2 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
B0939
BAFF active human, Animal-component free, recombinant, expressed in Nicotiana, >97% (SDS-PAGE)
SRP3305 BAFF human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)
WH0000718M1
Monoclonal Anti-C3 antibody produced in mouse, clone 5F9, purified immunoglobulin, buffered aqueous solution
SAB1403622
Monoclonal Anti-C3 antibody produced in mouse, clone 5F9, ascites fluid
SAB4700732 Monoclonal Anti-CD23 antibody produced in mouse, clone EBVCS-5, purified immunoglobulin, buffered aqueous solution
SAB1403808
Monoclonal Anti-FCER2 antibody produced in mouse, clone 2A7, purified immunoglobulin, buffered aqueous solution
SAB4100595
Monoclonal Anti-FCER2 antibody produced in mouse, clone FCER2-A577, culture supernatant
SAB1408993
Monoclonal Anti-FCER2 antibody produced in mouse, clone S51, ascites fluid, solution